Airfinity launches world’s first obesity data and analytics platform
24 janv. 2024 04h57 HE
|
Airfinity
London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market. ...
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
04 janv. 2024 05h59 HE
|
Novo Nordisk A/S
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and...
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
03 janv. 2024 07h33 HE
|
Arch Biopartners
TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the...
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
13 déc. 2023 07h25 HE
|
Arch Biopartners
TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to...
Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine
11 nov. 2023 08h31 HE
|
Novo Nordisk A/S
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity...
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
10 nov. 2023 01h30 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg,...
Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences
16 oct. 2023 07h00 HE
|
Novo Nordisk A/S
Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension...
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
10 août 2023 06h00 HE
|
Novo Nordisk A/S
Bagsværd, Denmark and Montreal, Canada, 10 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in...
Mexico Insulin Drugs and Delivery Devices Market Revenues to Reach USD 566.91 million by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
09 août 2023 09h30 HE
|
Mordor Intelligence
Hyderabad, Aug. 09, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Mexico Insulin Drugs and Delivery Devices Market Report (2023-2028)," the market is estimated at USD...
Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide
18 avr. 2023 07h10 HE
|
Arch Biopartners
TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel...